CBI suspends Deputy SP Devender Kumar | WeForNews | Latest News, Blogs CBI suspends Deputy SP Devender Kumar – WeForNews | Latest News, Blogs
Connect with us

India

CBI suspends Deputy SP Devender Kumar

Published

on

CBI

New Delhi, Oct 23: The Central Bureau of Investigation (CBI) on Tuesday suspended its Deputy Superintendent of Police Devender Kumar who is facing bribery allegations. 

“As per due procedure, Devender Kumar is suspended”, the CBI said.

Earlier in a day, Kumar was sent to seven days CBI custody over the bribery allegations involving its Special Director Rakesh Asthana to settle a case of controversial meat exporter Moin Qureshi.

Yesterday, the probe agency had arrested Kumar in connection with the Moin Qureshi case on the allegation of falsification of records.

As per the Central Bureau of Investigation, Kumar fabricated the statement of Sathish Sana, a witness in the Qureshi case, showing he recorded the statement on September 26 in Delhi.

However, the probe has revealed that Sana was not in Delhi. He was in Hyderabad on that day and joined the investigation only on October 1.

Kumar’s arrest comes a day after the CBI lodged an FIR against Asthana, Kumar and two others under sections pertaining to Prevention of Corruption Act.

The CBI has alleged that bribes were taken at least five times in December 2017 and October this year to settle a case of Qureshi.

WeForNews

India

PM Modi condoles loss of lives due to hospital fire in Rajkot

Praying for a quick recovery of the injured. The administration is ensuring all possible assistance to those affected.”

Published

on

Narendra Modi

The Prime Minister Shri Narendra Modi has expressed deep grief over the loss of lives due to a hospital fire in Rajkot.

In a tweet, the Prime Minister said, “Extremely pained by the loss of lives due to a hospital fire in Rajkot. My thoughts are with those who lost their loved ones in this unfortunate tragedy.

Praying for a quick recovery of the injured. The administration is ensuring all possible assistance to those affected.”

Continue Reading

Cities

Gujarat: Five Covid-19 patients killed as fire breaks out at Rajkot hospital

Thirty other coronavirus patients undergoing treatment at the hospital were rescued, an official said.

Published

on

rajkot hospital fire

Rajkot, Gujarat: Five patients were killed after a fire broke out in the ICU of a designated Covid-19 hospital in Gujarat’s Rajkot in the early hours of Friday. Chief Minister Vijay Rupani has ordered a probe into the incident.

Thirty other coronavirus patients undergoing treatment at the hospital were rescued, an official said. The fire is under control, however, the cause of the fire is yet to be ascertained.

The fire broke out in the ICU of Uday Shivanand Hospital in Mavdi area, where 33 patients were admitted. Seven of the patients were admitted to the ICU, fire brigade official J B Theva said. “We rushed to the spot and rescued 30 patients after a call informing about the fire was received. Three patients died inside the ICU,” he said.

The rescued patients have been shifted to other COVID-19 hospitals, he added.

In August, eight coronavirus patients had died in a huge fire that broke out in the intensive care ward of Shrey Hospital in Ahmedabad’s Navrangpura area.

PM Modi had condoled the deaths in his home state. “Saddened by the tragic hospital fire in Ahmedabad. Condolences to the bereaved families. May the injured recover soon. Spoke to CM @vijayrupanibjp Ji and Mayor @ibijalpatel Ji regarding the situation. Administration is providing all possible assistance to the affected (sic),” he had tweeted.

The Prime Minister’s office had also announced that an ex-gratia of ₹ 2 lakh each from PMNRF for the next of kin of those who have lost their lives due to the hospital fire in Ahmedabad. ₹ 50,000 each for those injured due to the hospital fire.

Continue Reading

Health

Oxford vaccine viable even at 60-70% efficacy: Serum Institute

The PM visit will be followed by a visit by ambassadors and High Commissioners from around 100 countries, Pune Divisional Commissioner Saurabh Rao said.

Published

on

Vaccine Covid

The AstraZeneca-Oxford vaccine candidate, even at the lowest efficacy of 60-70 per cent, is a viable one against the novel coronavirus, the Serum Institute of India (SII) said on Thursday.

SII has partnered with the University of Oxford and AstraZeneca for the manufacture and distribution of the vaccine candidate.

“Even though the lowest efficacy results are at 60-70%, it is a viable vaccine against the virus. That said, varied age groups with different dosage forms will result in slight variations and efficacy. We must be patient and not panic,” SII said in a statement.

Explained

India trial results not in

The efficacy results of AstraZeneca were based on trials being conducted in the United Kingdom and Brazil. It does not include the trials of the same vaccine being conducted by the Serum Institute in India. The results of the Indian trials are expected to come out in December.

The statement — a couple of days before PM Narendra Modi is scheduled to visit the company — comes amid an acknowledgment on Wednesday by AstraZeneca of a key error in the dosage received by some of the study participants of its Covid-19 vaccine candidate AZD1222 (named Covishield in India).

According to partial results announced on Monday from ongoing trials in the UK and Brazil, the vaccine showed a striking difference in efficacy, depending on the amount delivered. A regimen of two full doses given a month apart was 62 per cent effective while participants who received half a dose of the vaccine in the first round and then the full dose a month later were found to be 90 per cent less likely to develop Covid-19. The average efficacy was pegged around 70 per cent.

But on Wednesday, according to reports, AstraZeneca admitted that the half dose was an error since some of the vials did not have the right vaccine concentration.

In its statement, SII said there were no concerns about the trial in India.

“The Indian trials are running smoothly with strict adherence to all the necessary processes and protocols. So far, there are no concerns. However, we are going through the data that is available and will make a further statement, if needed,” the statement said.

Phase 3 trials are underway across 17 sites in the country and data on the Indian trials should be out in a month or so, SII CEO Adar Poonawalla had earlier told The Indian Express.

While scientists and experts say a vaccine with efficacy of 60 per cent and above is good, they have, however, raised concerns over the company’s communication strategy.

When contacted, Dr Gagandeep Kang, virologist and professor of Christian Medical College, Vellore, said, “You need to be absolutely straight upfront and transparent. We have learnt that the low dose in the Oxford study with higher efficacy was an accident. To first say that low dose gives 90 per cent efficacy and later say that the dose was an error creates doubt about the process that is unnecessary.”

Saying she “trusted the researchers at Oxford”, Kang said, “Usually when the researchers at Oxford work on vaccines, they go all the way through Phase 1 and sometimes through Phase 2 of the trial on their own. I understand that in this case, they were advised to not do everything on their own and as early as possible link up with a large vaccine company. Oxford started to work with AstraZeneca and this error in dosing may have happened in that switch from doing early phase studies themselves and the later trials with AstraZeneca. This would need to be informed to the regulators and in the trial registry.”

However, none of this is any reason to dismiss the vaccine, she said. “This is not a vaccine that should be put in the dustbin just because of 60 per cent efficacy. It is a good vaccine that has exceeded the WHO and FDA benchmarks. There is a lot more data to come and we will learn more when it does,” she said.

Virologist Dr Shahid Jameel said he was intrigued by the results. “As a scientist, I am now thinking what sort of response would one get if the first dose was even smaller – half of what they give — whether by design or accident, I don’t care. Would one get an equal or better response then?” Dr Jameel told.

Calling the results a “blessing in disguise”, he said, “The advantage is that if half or quarter dose gives a better response, then there would be twice as many vaccine doses to vaccinate people. That is a big plus. Many scientific discoveries have happened serendipitously,” he said.

On Saturday, Prime Minister Narendra Modi is set to visit Serum Institute of India “to understand the process of vaccine production and distribution”. Officials said the PM would reach around 1 pm and depart around 2.30 pm.

The PM visit will be followed by a visit by ambassadors and High Commissioners from around 100 countries, Pune Divisional Commissioner Saurabh Rao said.

Continue Reading
Advertisement

Most Popular

Corona Virus (COVID-19) Live Data

COVID-19 affects different people in different ways. Most infected people will develop mild to moderate illness and recover without hospitalization.